SecBot SecBot
SECBOTREPLAY Home › Report › STOK

STOK · Stoke Therapeutics filed a 424B5 prospectus supplement to upsize its…

Stoke Therapeutics, Inc. · 424B5 filed Aug 3, 2026 at 17:04 ET

At the news

BEARISHIMPACT 6/10

424B5 filed Aug 3, 2026 at 17:04 ET

Stoke Therapeutics filed a 424B5 prospectus supplement to upsize its at-the-market (ATM) equity offering facility from $150M to $200M, replacing the prior March 2026 supplement. The company has already raised $146.4M in net proceeds from prior sales under the same Cantor Fitzgerald agreement. This filing signals ongoing dilution risk for existing shareholders, with new investors facing immediate dilution of $21.05 per share at the current price of $28.86.

  • Stoke upsized its ATM offering to up to $200,000,000 in aggregate common stock sales, replacing the prior $150M facility.
  • The company has already sold ~4.7 million shares for aggregate net proceeds of $146.4 million under the prior supplement.
  • At the assumed offering price of $28.86 per share, new investors would incur immediate dilution of $21.05 per share.
  • Proceeds are earmarked for general corporate purposes including R&D, clinical development, and commercialization preparations.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access